Bitcoin has stayed above the $80,000 level for over three weeks as of mid-October 2026, despite some profit-taking by short-term holders. While Bitcoin's price dipped slightly in early October, it repeatedly tested the $80,000 support level without breaking it. A sustained drop below $80,000 could shift focus to a lower short-term holder cost basis near $75,000. Large transfers from long-held wallets have raised questions about potential supply, but these movements do not confirm actual selling. The market now watches if Bitcoin can maintain this key support to gauge near-term price direction.
Bitcoin's price stability above $80,000 is noted here alongside Pluang's market data as of Oct 14, 2026 01:03 WIB. Among 50 major cryptocurrencies on Pluang, 13 rose and 36 fell today. Polkadot (DOT) traded at Rp20.771 with a 4.31% decline and a typical hold time of 121 days, while Theta Network (THETA) was priced at Rp3.688, down 4.21%, and Neo (NEO) stood at Rp43.104 with a 4.13% drop and 100% buy order activity.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
